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 ABSTRACT 
BACKGROUND: There were an estimated 207 million cases of malaria in 2012 of which 
91% were due to Plasmodium falciparum. Antimalarial drug resistance constitutes a major 
problem in the efforts to control malaria. Drug resistance typically arises by the gradual 
accumulation of genetic changes that enable parasites to tolerate gradually increasing drug 
concentrations until fully resistant parasites develop. The aim of this thesis was to determine 
temporal and geographic frequencies of genetic polymorphisms linked to P. falciparum and 
P. vivax resistance after exposure to various antimalarial drugs. 
METHODS: Polymorphisms in P. falciparum and P. vivax multidrug resistance 1 (pfmdr1 
and pvmdr1), dihydrofolate reductase (pfdhfr and pvdhfr) genes, P. falciparum chloroquine 
resistance transporter (pfcrt), dihydropteroate synthase (pfdhps), V-type H+ pyrophosphatase 
(pfvp2), Na+/H+ exchanger-1 (pfnhe1) and multidrug-resistant protein 1 (pfmrp1) genes were 
determined in field samples. P. falciparum and P. vivax samples from Honduras, where drug 
resistant malaria has not been detected, were analysed for paper I. Samples from Honduras, 
Colombia, Liberia, Guinea-Bissau, Tanzania, Iran, Thailand and Vanuatu that represented 
varying origins and frequency of chloroquine (CQ) resistant P. falciparum malaria were 
analysed for paper II. Samples from 4 villages in Liberia in 1978 after children were 
administered village specific treatments of CQ, pyrimethamine (PYR), chlorproguanil or 
placebo monthly for 2 years were used for paper III. Samples (n=1806) from virtually all 
children aged <15 years with uncomplicated malaria between 2003 and 2012 in Guinea-
Bissau were analysed for paper IV. Artemether-lumefantrine replaced an effective high dose 
CQ treatment in Guinea-Bissau in 2008 but quinine was prescribed to 43% of the children 
between 2010 and 2012. 
RESULTS and CONCLUSIONS: 
Paper I: No genetic polymorphisms associated with CQ or sulphadoxine-pyrimethamine 
(SP) resistance were found indicating that P. falciparum remains CQ sensitive in Honduras. 
CQ resistance associated pvmdr1 976F (7/37) and SP resistance associated pvdhfr 57L+58R 
(2/57) were detected suggesting a degree of tolerance to CQ and SP in P. vivax. 
Paper II: Pfvp2 SNPs were found in only 20/367 patient samples. Nevertheless, the V405 + 
K582 + P711 haplotype was associated with pfcrt 76T (P=0.007) in line with previous in 
vitro data. However, the limited variation suggests that the results should be interpreted with 
caution. 
Paper III: Pfcrt 72-76 CVIET without other downstream resistance associated SNPs 
occurred in 1/178 samples from the village using CQ in Liberia. CVIET might have 
developed in Liberia in 1978 but the haplotype was not detected in 1981 suggesting that it 
probably did not provide a selective advantage in this area. Pfdhfr 108N was significantly 
lower (1/46, P=0.001) in the Liberian village using PYR compared with other villages 
(64/123). Pfdhfr 108N probably occurred as a wild type allele prior to the introduction of 
antifolates in Liberia. Decreased pfdhfr 108N frequency concurrently with the development 
of in vivo PYR resistance suggests a resistant mechanism other than pfdhfr point mutations. 
Paper IV: Between 2003 and 2007 pfcrt K76T and pfmdr1 N86Y frequencies were stable in 
Guinea-Bissau. After 2007, mean annual pfcrt 76T (2457%) and pfmdr1 86N (7283%) 
frequencies increased (p<0.001). Increased pfcrt 76T was probably driven by quinine that 
was as commonly used artemether-lumefantrine. Pfmdr1 86+184 NF frequency increased 
(3966%) between 2003 and 2011 (p=0.004), possibly driven by artemether-lumefantrine. 
 
 

 LA PROBLEMÁTICA DE LA MALARIA RESISTENTE AL 
TRATAMIENTO 
La malaria o paludismo es una enfermedad producida por un parásito llamado Plasmodium y 
es una de las enfermedades infecciosas más importantes a nivel mundial. En los últimos 
quince años los enormes esfuerzos para controlar la malaria han permitido que el número de 
casos y muertes se hayan reducido significativamente. A pesar de ello, la malaria representa 
una amenaza constante para la vida y salud del 40% de la población mundial que vive en los 
90 países donde se transmite la malaria. Actualmente mueren alrededor de 600 000 personas 
al año debido a la malaria, la mayoría son niños menores de 5 años y mujeres embarazadas. 
Uno de los pilares fundamentales en el control de la malaria ha sido el acceso a un 
tratamiento efectivo. Desde 1890 la quinina constituyó el tratamiento principal para tratar la 
malaria hasta el descubrimiento de la cloroquina en 1947. A partir de entonces la cloroquina 
se usó extensamente para prevenir y tratar la malaria. La cloroquina es segura, barata y se 
considera que ha salvado incontables millones de vidas, convirtiéndola en uno de los 
tratamientos más exitosos jamás producidos. Lamentablemente a finales de los años 50 los 
parásitos se volvieron resistentes al tratamiento, es decir, la cloroquina empezó a dejar de 
funcionar. Este fenómeno ocurrió simultáneamente en Colombia, Venezuela, en la frontera de 
Tailandia con Cambodia y en algunas regiones del Pacífico. Para los años 80 este fenómeno 
de resistencia se había difundido en todas las áreas con casos de malaria de América del Sur, 
Asia y el este de África. Hacia los años 90 la resistencia a la cloroquina constituyó un serio 
problema en muchos de los países del oeste de África. Curiosamente, al norte del Canal de 
Panamá la cloroquina todavía es efectiva para tratar la malaria. Debido a este gran problema 
de resistencia la Organización Mundial de la Salud ahora recomienda el uso de terapias 
combinadas con artemisina (TCA). 
Una definición de resistencia es “la habilidad de un parásito de sobrevivir o multiplicarse a 
pesar de tomar el tratamiento siguiendo las debidas recomendaciones”. Pero la resistencia no 
ocurre en un solo paso, probablemente ocurre gradualmente cuando el parásito debe de 
ajustar su funcionamiento al estar bajo la presión del tratamiento. Estos ajustes ocurren por lo 
general en el ADN, pequeños cambios o mutaciones que poco a poco se van acumulando 
haciendo que el parásito empiece a tolerar el tratamiento hasta que eventualmente se 
convierte en resistente al tratamiento. Este proceso puede tomar de uno a doce años, como ha 
ocurrido en algunos de los parásitos que causan la malaria. 
En este trabajo estudiamos mutaciones de los parásitos de la malaria que están asociados a 
resistencia al tratamiento y que han ocurrido desde 1978 hasta el 2012 en ocho diferentes 
países del mundo. Para este trabajo se tomó pequeñas muestras de sangre a personas con 
malaria en los siguientes países e intervalos de tiempo: Honduras (2004-2006 y 2009), 
Colombia (2001-2005), Liberia (1978 y 1981), Guinea Bissau (2003-2012), Tanzania (2008), 
Irán (2001-2002), Tailandia (2002-2008) y Vanuatu (2002); países que han usado diferentes 
tratamientos para combatir la malaria. En Honduras, Irán, y Vanuatu el tratamiento que se usó 
fue la cloroquina. En Colombia se usó amodiaquina combinada con sulfadoxina-
pirimetamina. En Liberia se utilizaron tres diferentes tratamientos: cloroquina, pirimetamina 
 
y clorproguanil. En Guinea-Bissau se utilizó una dosis inusualmente alta de cloroquina hasta 
que en el 2008 se introdujo TCA y del 2010 al 2012 además de las TCA se usó quinina. En 
Tanzania se utilizó como tratamiento TCA. Con la sangre obtenida de las personas con 
malaria se obtuvo el ADN de los parásitos y se realizaron diferentes metodologías de 
laboratorio que permitieron identificar las diferentes mutaciones. 
Los resultados más importantes de este trabajo se detallan a continuación. En la mayoría de 
los parásitos que provenían de Honduras no se encontraron mutaciones que están 
relacionados con resistencia al tratamiento, por lo tanto el tratamiento que se utiliza en el país 
es adecuado. En Liberia, a pesar de que se observó un caso resistente a la cloroquina en 1978 
no se encontraron más casos en 1981, lo que significa que los parásitos resistentes a la 
cloroquina no lograron establecerse en el área estudiada. Sin embargo, si se encontraron 
parásitos resistentes a la pirimetamina. Lo que nos llamó la atención con respecto a estos 
parásitos resistentes a la pirimetamina es que las mutaciones de los parásitos fueron diferentes 
a los que anteriormente se han encontrado en parásitos de otros países. Esto nos hace pensar 
que los parásitos en esta área encontraron una forma alternativa para volverse resistentes al 
tratamiento. En Guinea Bissau, hasta el 2008 la cantidad de parásitos resistentes a la 
cloroquina fue mucho menor a la cantidad observada en los años posteriores. Lo anterior fue 
probablemente debido al empleo inusual de una dosis alta de cloroquina. Sin embargo, el 
aumento de parásitos resistentes observados a partir del 2008 se debió probablemente a las 
dosis inadecuadas de quinina empleadas para tratar a las personas con malaria. La quinina y 
la cloroquina son tratamientos muy parecidos y cuando uno de estos se usa inadecuadamente, 
por ejemplo en dosis bajas, los parásitos no desaparecen completamente del cuerpo de las 
personas. Los parásitos que quedan y sobreviven en estas dosis bajas de tratamiento son los 
que eventualmente cambian hasta convertirse en resistentes. 
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 1 BACKGROUND 
1.1 The Plasmodium parasite 
Malaria is an infectious disease caused by a parasite of the genus Plasmodium. This 
protozoan is transmitted to humans by the bite of blood feeding female anopheline 
mosquitoes. There are more than 140 of plasmodium species that can infect birds, reptiles and 
mammals. Only five species have been shown to infect humans: P. falciparum, P. vivax, P. 
ovale, P. malariae and P. knowlesi [1]. The parasite was discovered in human blood by 
Alphonse Laveran in 1880. Later, in 1898, the parasite was observed in the mosquito by 
Ronald Ross who completed a description of the life cycle. 
1.1.1 Malaria Vectors 
There are over 500 hundred species of Anopheles mosquitoes. Worldwide ~40 anopheline 
species have been documented to transmit parasites to humans with varying efficiency [1]. 
The female anopheles needs a blood meal for egg production. Some vectors prefer blood 
meals from humans (anthropophilic) whilst others prefer to feed from animals (zoophilic). 
Some of the vectors have the tendency to enter and rest inside houses (endophilic) and other 
rest outside (exophilic) after taking a blood meal. Most vectors feed at night but habits vary 
with species [2]. Anopheles species with the greatest capacity to transmit Plasmodium are 
found in the Amazon (An. darlingi) and Africa (the species complex of An. gambiae). In 
Southeast Asia a highly efficient vector is An. dirus [1]. 
1.1.2 Life cycle 
The female Anopheles mosquito injects sporozoites (8-15, up to 100 in some cases) that are 
present in the saliva of the insect [3, 4]. Sporozoites infect the liver cells where they may 
remain dormant (hypnozoites) or produce schizonts and merozoites. The liver cycle takes 5-
15 days (up to 3 years if hypnozoites from P. vivax or P. ovale exist). When liver cells 
rupture, ~10 000 – 30 000 merozoites from each schizont are released into blood and infect 
the erythrocytes. In the erythrocytes, the young rings mature into trophozoites. These 
trophozoites develop via schizonts into merozoites in erythrocytes which ultimately burst 
releasing 6-36 merozoites per schizont. The released merozoites immediately re-invade new 
red blood cells and start a new asexual cycle. The infection expands logarithmically at 
approximately 10-fold per cycle [5]. This expansion is determined by the sub-population of 
erythrocytes invaded. P. ovale and P. vivax infect immature erythrocytes whereas P. malariae 
infects mature erythrocytes. P. falciparum infects both. The erythrocytic cycle takes 48 hours 
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 or 72 hours (P. malariae). Some of the merozoites transform into male and female 
gametocytes. 
Gametocytes are ingested by the female mosquito taking a blood meal. Female gametocytes 
transform into ookinetes that are fertilized forming oocysts in the gut. Oocytes produce 
sporozoites that migrate to the salivary gland, ready to infect another host. Malaria can also 
be transmitted by transfusion and transplacentally. 
 
Figure 1 - The life-cycle of Plasmodium falciparum. The main phases in the liver and in the red 
blood cells (asexual and sexual erythrocytic stages) of the human host, and in the gut and in the 
salivary glands of the mosquito host are depicted. Reprinted from Trends in Parasitology [6], with 
permission from Elsevier. 
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 1.2 Clinical presentation of malaria 
In clinical practice, malaria is defined as uncomplicated or severe. The first symptoms of 
malaria are nonspecific: a lack of a sense of well-being, headache, fatigue, abdominal 
discomfort and muscle aches are followed by fever. The classic malarial paroxysms, in which 
fever spikes, chills, and rigors occur at regular intervals, are unusual and suggest infection 
with P. vivax or P. ovale. Most patients with uncomplicated infections have few abnormal 
physical findings other than fever, anaemia, and in some cases palpable spleenomegaly [1]. 
Anaemia is common among young children living in areas with stable transmission, 
particularly where there is resistance to available antimalarials [7]. 
Severe malaria is an acute life threatening form of malaria with high (~ 10%) mortality in 
young children [8]. Severe malaria is typically considered to be a feature of P. falciparum 
though P. vivax can also result in severe disease and death. The characteristics of severe P. 
vivax are similar to those of severe P. falciparum malaria [9-11]. Studies from Indonesia, 
Papua New Guinea, Thailand and India where both species coexist, showed that 20-40% of 
malaria admissions were due to P. vivax mono-infections. In addition, a review showed that 
mortality was 0.8-1.6% and 1.6-2.2% due to mono-infections of P. vivax and P. falciparum 
respectively [12]. The underlying mechanisms of severe manifestations in P. vivax are not 
fully understood. 
1.3 Global Malaria Burden 
Malaria generally occurs in tropical and subtropical areas, is commonly associated with 
poverty and represents a major burden to economic and social development, costing an 
estimated sum greater than US$ 2.5 billion for the year 2013 [9, 13]. 
In 2012 it was estimated that 3.4 billion people were at risk of the disease. There were an 
estimated 207 million cases of malaria worldwide of which 91% were due to P. falciparum. 
Though P. falciparum is the most common malaria species, P. vivax is the most widespread. 
P. ovale, P. malariae and P. knowlesi are less common. The African region contributes the 
majority of malaria cases (81%) [9, 14]. Worldwide, an estimated 627 000 deaths were 
attributed to malaria during 2012. Approximately 77% of malaria associated mortality 
occurred in children under 5 years of age and 91% of the deaths were in Africa [9]. 
In 2010 it was estimated that 2.49 billion people were at risk of P. vivax malaria infection. In 
2012 it was estimated that from the 207 million malaria cases 9% were due to P. vivax [9]. 
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 The majority of the cases are concentrated in Southeast Asia, Middle East and the Pacific 
[15]. In the Americas, P. vivax accounts for around 70% of malaria cases [9]. 
1.4 Malaria control  
Progress in reducing malaria worldwide has been remarkable. There are 79 countries that 
have eliminated malaria since 1954 and the proportion of the world’s population who live in 
malaria-endemic regions has decreased from 70% to 50% [16]. Malaria eradication was first 
undertaken by the WHO between 1955 and 1969. The malaria eradication programme used 
vector control and effective treatment as primary tools to manage malaria. Despite many 
gains made during the program, the eradication effort was terminated in 1969. Among the 
reasons for stopping the program were widespread resistance to available insecticides, wars, 
massive population movements, difficult to obtain funding and finally the emergence of CQ 
resistance in the 1960s. [17] 
In the last 15 years there has been renewed interest and action to support malaria research, 
control, and eradication. The current malaria control strategy was launched in the early 2000s 
and included drug use, vector control, confirmation of malaria diagnosis, environmental 
modification and political and social mobilization [9, 18]. The strategy appears to have been 
successful. It is estimated that between 2000 and 2012, malaria mortality rates fell by 42% in 
all age groups and by 48% in children under 5 years [9]. 
1.4.1 Vector control 
The goals of malaria vector control include protection of individual people against infective 
malaria mosquito bites and reduction of the intensity of local malaria transmission at 
community level. This should be achieved by reducing the longevity and density of the vector 
and human-vector contact. The two most powerful and most broadly applied interventions are 
long-lasting insecticidal nets (LLINs) and indoor residual spraying (IRS) [9]. LLINs have 
been shown to decrease morbidity and mortality in various malaria transmission settings 
thereby having a major impact on the malaria burden [19-22]. IRS involves application of 
insecticides to the inner surfaces of dwellings, where many vector species of Anopheles 
mosquito tend to rest after taking a blood meal. This strategy has also proved to effectively 
reduce malaria transmission in areas with low and variable/seasonal transmission [23-25]. 
Worryingly, recent studies in Senegal, Benin and Zambia showed that the prevalence of 
insecticide tolerant mosquitoes and P. falciparum incidence increased after the introduction 
of LLINs [26-28]. 
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 1.4.2 Diagnosis of malaria 
Prompt parasitological confirmation by microscopy or rapid diagnostic tests (RDTs) is 
recommended before treatment is started. In settings with limited health facility access, 
diagnosis and treatment should be provided at community level through a programme of 
community case management [29]. 
1.4.3 Treatment of uncomplicated malaria. 
P. falciparum has developed resistance to CQ, followed by SP and then by mefloquine when 
used as monotherapy. The WHO therefore recommends artemisinin based combination 
therapy (ACT) to treat uncomplicated P. falciparum malaria [30, 31]. In pre-elimination or 
elimination programs a single dose of primaquine is also recommended [29] 
The choice of ACT should be based on the efficacy of the combination in the country or area 
of intended use. Artemisinin and its derivatives should not be used as oral monotherapies for 
the treatment of uncomplicated malaria as poor adherence to the required 7 days of treatment 
results in partial clearance of malaria parasites which will promote resistance to this critically 
important class of antimalarials [29]. 
P. vivax malaria should be treated with CQ in areas where CQ is effective. When CQ 
resistance is present, an appropriate ACT should be used. In order to prevent relapses a 14 
day course of primaquine should be used in combination with both CQ and ACT [29]. 
1.4.4 Treatment of severe malaria  
Severe malaria should be treated with a parenteral artemisinin derivatives (artesunate and 
artemether) followed by a complete course of an effective ACT as soon as the patient can 
take oral medications. If artemisinin derivatives are not available parenteral quinine (QN) or 
quinidine can be used as an alternative. Where complete parenteral treatment of severe 
malaria is not possible patients should be given pre-referral treatment and immediately be 
referred to an appropriate facility for further treatment. Options available for pre-referral 
treatment are: Rectal or intramuscular artesunate, intramuscular QN or artemether [29]. 
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 1.5 Antimalarial drugs discussed in this thesis 
1.5.1 Quinolines and related compounds 
The first effective chemotherapy for treatment of malaria was extracts from the Cinchona 
bark tree. The extract was imported from South America to Europe in the mid 17th century 
where it became popular for the treatment of fevers including malaria. In 1820 pure QN was 
isolated from the Cinchona bark and replaced the extract in the treatment of malaria [30]. The 
basic quinoline ring structure has provided a group of synthetic antimalarials (CQ, 
amodiaquine, piperaquine, mefloquine and primaquine) collectively named quinolines. Based 
on more loosely related ring systems the antimalarials halofantrine and lumefantrine have 
also been synthesized [32]. 
QN acts on mature trophozoites and does not prevent sequestration or further development of 
ring stages of P. falciparum [29]. It does kill sexual stages of P. vivax, P. malariae and P. 
ovale but not mature gametocytes of P. falciparum [29]. QN is usually used to treat severe 
malaria. In combination with antibiotics it is used as second line treatment of uncomplicated 
malaria and it is also used during the first trimester of pregnancy [29]. Though a combination 
of QN and an antibiotic is recommended, QN is commonly used as monotherapy in most 
African countries [33]. 
CQ has been used extensively for the treatment and prevention of malaria since 1947. It is 
safe, cheap and is estimated to have saved countless millions of lives. As such it is one of the 
most successful drugs ever produced [34]. Widespread resistance has now rendered it 
virtually useless against P. falciparum infections in most parts of the world but not north of 
the Panama Canal. It is still efficacious for the treatment of P. vivax, P. ovale and P. malariae 
infections in most parts of the world.  
Amodiaquine (AQ) is a potent blood schizonticide that was developed in the late 1940s and 
has been used for the treatment of uncomplicated malaria particularly in Africa [35]. When 
used for malaria prophylaxes AQ can cause neutropenia and mainly for that reason it was not 
used for many years. However, it has been revived as part of an ACT. 
Mefloquine is effective against all forms of malaria [36]. Mefloquine was introduced to treat 
patients with CQ resistant parasites. It was initially used as monotherapy in areas of low 
malaria transmission [37]. Due to resistance it is now principally used in combination with 
artesunate to treat P. falciparum in Southeast Asia (Cambodia, Malaysia, Myanmar, Thailand 
and Vietnam) and South America (Bolivia, Brazil, Colombia, Peru and Venezuela) [9] 
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 Lumefantrine is a blood schizonticide that was first synthesized in China and first mentioned 
in scientific literature outside China in 1990. It is only available as an oral preparation co-
formulated with artemether. This ACT is highly effective against P. falciparum and a corner 
stone of ACT in Africa [29].  
The quinolines do not eradicate hypnozoites unlike primaquine that was developed during the 
Second World War. Primaquine is effective against intrahepatic forms of all types of malaria 
parasite. It is also gametocytocidal against P. falciparum and has significant blood stages 
activity against P. vivax (and some against asexual stages of P. falciparum). The haemolytic 
effect in patients with glucose-6-dehydrogenase deficiency (G6PD) and gastrointestinal 
intolerance limits its use. 
1.5.1.1 Quinoline mechanism of action 
CQ has been the most thoroughly studied antimalarial with the aim of understanding its 
parasiticidal effect and the mechanisms of CQ resistance in malaria. CQ is a week base that 
moves rapidly across cell membranes and accumulates in the acidic environment of the 
digestive vacuole because it becomes protonated there [38]. In the digestive vacuole CQ 
disrupts the detoxification of haem when haemoglobin is digested by the parasite [39]. This 
results in haem complexes that are lethal to the parasite [40]. The mechanism of CQ activity 
against blood stages of P. vivax remains unknown [41]. QN, amodiaquine and piperaquine 
are believed to have similar modes of action to that of CQ [42]. Mefloquine, halofantrine and 
lumefantrine have also been shown to inhibit the detoxification of haem but they also appear 
to target other process in the parasite [43, 44]. 
1.5.2 Antifolates 
The antifolates are compounds that bind to enzymes necessary for parasite folate 
biosynthesis. The principal antifolate drugs used against malaria are sulphadoxine and 
pyrimethamine (SP). 
Sulphadoxine is a structural analogue and competitive antagonists of p-aminobenzoic acid. It 
potentiates the schizontocidal effect and improves clinical response of pyrimethamine (PYR) 
when treating P. falciparum infection [45-47]. In 1951 PYR was shown to be effective for the 
treatment of P. falciparum [48, 49]. It inhibits dihydrofolate reductase (pfdhfr) thus indirectly 
blocking the synthesis of nucleic acids in the malaria parasite. It is a slow-acting blood 
schizontocide and is possibly active against pre-erythrocytic forms. Furthermore, it inhibits 
sporozoite development in the mosquito vector. During the 1950–1960s, PYR was mainly 
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 used for prophylaxis against P. falciparum infection or for mass drug administration because 
CQ was effective in all endemic regions [50-52]. The antifolate combination of sulphadoxine 
and pyrimethamine (SP) was first introduced in Thailand in the 1960’s where the frequency 
of CQ-resistant P. falciparum infections had reached an unacceptable level. 
Chlorproguanil (CPGN) is a chloro- derivative of proguanil that is metabolised to 
chlorcycloguanil. CPGN works by blocking the synthesis of tetrahydrofolate, essential in 
DNA synthesis. CPGN has recently gained more interest, mainly in combination with 
dapsone. CPGN-dapsone has been shown to be effective for the treatment of SP resistant 
parasites [29, 53, 54]. 
1.5.3 Artemisinin 
Artemisinin, also known as qinghaosu, is a semisynthetic drug extracted from the leaves of 
Artemisia annua (sweet wormwood). It has been used in China for the treatment of fever for 
over a thousand years and artemisinin derivatives are now the cornerstone of antimalarial 
combination therapy. It is a potent and rapidly acting blood schizontocide and is active 
against all Plasmodium species. It has an unusually broad activity against asexual parasites. 
Furthermore, it kills P. falciparum gametocytes [55]. The mechanism of action of artemisinin 
is not fully understood [56, 57]. Commonly used artemisinin derivatives are 
dihydroartemisinin, artemether, and artesunate. The two latter derivatives are in vivo 
converted back to dihydroartemisinin. The 5 ACTs currently recommended are artemether + 
lumefantrine, artesunate + amodiaquine, artesunate + mefloquine, artesunate + sulphadoxine-
pyrimethamine and dihydroartemisinin + piperaquine [29]. 
1.6 Antimalarial drug resistance 
One commonly used definition of clinical drug resistance is “the ability of a parasite strain to 
survive and/or to multiply despite the administration and absorption of antimalarial drug in 
the dose normally recommended.” Antimalarial drug resistance is not necessarily the same as 
malaria “treatment failure”, which is a failure to clear malarial parasitaemia and/or resolve 
clinical symptoms despite the administration of an antimalarial. So while drug resistance may 
lead to treatment failure, not all treatment failures are caused by drug resistance [58]. 
Drug resistance in malaria does probably not arise in a single step, but as a long process 
during which parasites become gradually more and more tolerant to the drug in question. This 
is believed to be the result of a gradual accumulation of genetic changes as discussed below. 
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 The changes alter the natural function of a specific protein that in turn may require additional 
compensatory genetic changes. Eventually a fully resistant and fit parasite emerges. For P. 
falciparum this process typically takes 1-12 years [59]. 
The greatest problem with drug resistance occurs with P. falciparum but CQ resistant P. 
vivax is a developing problem [60]. There are very few reports on drug resistant P. malariae 
and P. ovale although there have also been very few studies. Of greatest concern at the 
moment are recent reports of P. falciparum that are resistant / tolerant to artemisinin and to 
ACT [61-67]. 
1.6.1.1 Development and spread of quinine resistance 
QN resistance was observed nearly 100 years ago when recrudescences were observed in 
Brazil [68]. Since the 1980’s there have been more reports of QN resistance or reduced 
susceptibility in vitro and in vivo in Southeast Asia [69-79] and South America [75, 76, 80-
84]. Since the 1990’s in vivo and in vitro resistance and reduced susceptibility has also been 
reported from Africa [76, 82, 85-97]. 
1.6.1.2 Development and spread of chloroquine resistance 
CQ resistant P. falciparum took a long time to develop (>10 years) [31] and only appears to 
have arisen 5 times [59]. In the late 1950s, CQ resistant P. falciparum was  identified at the 
Thai-Cambodian border and simultaneously in two different locations in South America 
(Colombia and Venezuela) [30]. In Pacific regions CQ resistance was first reported 1959–
1961 [98]. Resistance then spread to eastern parts of the Pacific region between 1976 and 
1980. By the mid 1970s CQ resistance was spread throughout Southeast Asia. All endemic 
areas in South America were affected by 1980 and almost all of Asia and the Pacific by 1989 
[31]. In Africa CQ resistance first appeared on the east coast in 1978 [99, 100]. During the 
early 1980s it spread throughout East Africa and by the early 1990s, CQ resistant P. 
falciparum became a serious emerging problem in many West African countries [59]. CQ 
resistance has been reported from wherever falciparum malaria is endemic, except Central 
America [101, 102]. 
P. vivax is still generally sensitive to CQ although sensitivity is decreasing in some areas. CQ 
resistant P. vivax was first described in 1989 when it was reported from Papua New Guinea 
[103]. Subsequently other reports from Indonesia confirmed those findings [104-106]. By 
2002 there were reports from Malaysia, Myanmar, Vietnam, India and Iran [107-111] and by 
2009 from Turkey and South Korea [112, 113]. In South America CQ resistance was first 
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 reported in 1996 from French Guyana [114]. By 2003 Brazil, Colombia and Peru had also 
reported cases of CQ resistant P. vivax [115-117]. The first reports from Africa were from 
Ethiopia and Madagascar in 2008 [118, 119]. 
1.6.1.3 Development and spread of pyrimethamine, sulphadoxine-pyrimethamine 
and chlorproguanil resistance 
PYR resistance appeared in Asia and East and West Africa during or shortly after trials of 
mass eradication or prophylaxis during the 1950’s and 1960’s. [120-125]. Cross-resistance 
between PYR and CPGN was noted in Ghana, Nigeria and Liberia during the same period 
[125, 126]. 
SP resistant P. falciparum were described on the Thai-Cambodia border in 1967, the same 
year that SP was introduced. SP resistance subsequently spread to other regions in Southeast 
Asia [31]. In 1996, high-level resistance was found simultaneously in a large part of 
Southeast Asia, Southern China and Amazon area [127, 128]. Lower degrees and frequencies 
of resistance were observed on the Pacific coast of South America [31]. Sensitivity to SP in 
Africa started to decline in the late 1980s following increased use of PYR-dapsone 
prophylaxis [31]. 
In early reports from the 1950’s P. vivax appeared to be resistant to SP. However, recently it 
was suggested that the early perception of poor efficacy may have been a product of 
confusion with the failure of SP to prevent relapse [129]. However, clinical failure following 
SP treatment has been reported from Papua New Guinea and Indonesia in 1992 [130, 131]. 
By 2005 resistance had also been reported from, Myanmar, Vietnam, Vanuatu and India 
[132, 133]. 
1.6.1.4 Artemisinin resistance 
In 2005, there was a report of reduced in vitro susceptibility to arthemeter in isolates from 
French Guyana and Senegal [134]. In vivo artemisinin resistance or perhaps more correctly 
tolerance or reduced susceptibility is characterized by a slower rate of parasite clearance. This 
has been described from Western Cambodia [63, 64, 135, 136], Thailand [137], South-eastern 
Burma and South-eastern Vietnam [138]. A recent report from Western Cambodia describes 
how the proportion of P. falciparum with reduced artesunate susceptibility increased over 
time. The study showed that mean parasite clearance time decreased from 2.6 hrs in 2001 to 
5.5 hrs measured between 2007 to 2010 [136]. 
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 1.6.2 Resistance associated genes 
P. falciparum and P. vivax parasites contain approximately 5 500 genes on 14 chromosomes. 
By 2002 more than 95% of P. falciparum’s genome was sequenced and sequencing of the P. 
vivax genome was completed in 2008 [139, 140]. Different genes from these parasites appear 
to be involved in resistance to different antimalarial drugs. 
Resistance appears to be caused by a change in the structure, function or quantity of a protein. 
The change in the protein is in turn mediated by genetic changes such as single nucleotide 
polymorphisms (SNP), gene amplifications and gene expression. An alteration in the 
structure of a protein may prevent the drug from binding to its target as in SP resistance [141, 
142]. An alternative mechanism is to enhance or block a transport protein so that a drug is 
removed from its site of action (e.g. CQ efflux from the DV) or prevented from entering into 
its site of action (e.g. import of CQ or QN in to DV) [143]. Changes in two genes may act in 
combination to produce a specific phenotype [144].  
1.6.2.1 Quinolines 
The two principle genes that appear to be involved in quinoline resistance are P. falciparum 
chloroquine resistance transporter (pfcrt) and P. falciparum multidrug resistance 1 (pfmdr1) 
[143]. Both are located in the membrane of P. falciparum’s digestive vacuole [143]. Both are 
believed to be transporters and different SNPs hinder or enable the transport of different 
quinolines [143]. 
Additional genes that have been suggested to be involved in quinoline resistance include the 
multidrug resistant-associated protein 1 (pfmrp1) as well as the Na+/H+ exchanger (pfnhe1). 
Both are located in the plasma membrane and it has been suggested that they participate in 
the efflux of metabolites (e.g. oxidised glutathione, CQ, QN, folates) out of the parasite. In 
addition pfmrp1 was suggested to efflux drugs out of the parasite [145-147]. 
The search for molecular markers of resistance in P. vivax has focused on the orthologs P. 
vivax multidrug resistance gene 1 (pvmdr1) and chloroquine resistance transporter gene 
(pvcrt-o) [41]. 
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 1.6.2.2 P. falciparum chloroquine resistance transporter – pfcrt 
More than 40 years were necessary to go from clinical recognition of CQ resistance to the 
molecular basis of the phenomena which was unravelled in 2000 when pfcrt was identified 
[148]. Pfcrt is located in the membrane of the DV and different haplotypes that contain 
between 4 and 10 mutations have been associated with CQ resistance around the world [59, 
143]. Specific haplotypes at positions 72-76 are linked to the regional evolution of CQ 
resistance [59] and the K76T SNP has been shown to be essential for CQ resistance in vivo 
and in vitro[149-152]. The replacement of Lysine (K) with Threonine (T) removes a positive 
charge enabling pfcrt to transport protonated CQ down its electrochemical gradient, out of the 
DV [153, 154]. The net result is lower nontoxic CQ concentrations in the DV and continued 
parasite growth. Recently the ordered evolution of the SNPs described K76T and N75E or 
N326D SNPs as the first step to drug resistance followed by additional SNPs and how these 
changes affected CQ transport [155]. 
Pfcrt has also been shown to influence susceptibility to other antimalarial drugs. 
Amodiaquine resistance is linked to pfcrt 76T just as CQ and allelic exchange experiments 
have linked pfcrt 76T to reduced susceptibility to mefloquine, artemisinin and QN [150, 156, 
157]. Furthermore, K76 has been linked to reduced susceptibility to lumefantrine [158]. 
1.6.2.3 P. falciparum multidrug resistance 1 – pfmdr1 
Before the discovery of pfcrt most attention was given to pfmdr1 [159]. The first pfmdr1 
polymorphism that was correlated to drug resistance was gene copy number [160-162]. 
Subsequently, multiple pfmdr1 copies were shown to be a molecular marker of in vitro and in 
vivo mefloquine resistance [62, 163]. Decreased in vitro susceptibility to lumefantrine, 
halofantrine, QN and artemisinin have also been linked to amplifications [62, 164, 165]. 
Furthermore, amplifications have been associated with an increased risk of treatment failure 
following use of arthemeter-lumefantrine [65, 166, 167]. 
Drug resistance associated SNPs in pfmdr1 include N86Y, Y184F, S1034C, N1042D, 
F1226Y and D1246Y. Various combinations of these SNPs have been shown to modulate the 
level of drug resistance/tolerance to QN, CQ, amodiaquine, mefloquine halofantrine 
lumefantrine [61, 62, 75, 168-184] and artemisinin [179-184]. SNPs in pfmdr1 do not confer 
CQ resistance [179, 180] however pfmdr1 N86Y together with pfcrt K76T has been 
associated with high levels of CQ resistance [185, 186]. 
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 1.6.2.4 P. falciparum V-type H+ pyrophosphatase – pfvp2 
Pfvp2 is a class of H+ pump found in plants and some protozoa [187-191]. Pfvp2 is located in 
the DV membrane and increased transcription of pfvp2 has been observed in vitro when P. 
falciparum are exposed to CQ [191] and lumefantrine [158]. Specifically a ten-fold up-
regulation of pfvp2 was observed when the CQ resistant (pfcrt 76I) P. falciparum 106/1 clone 
was exposed to CQ but no up-regulation was seen with the CQ sensitive 106/1 (pfcrt 76K) 
clone. A two-fold up-regulation of pfvp2 was seen when the lumefantrine tolerant P. 
falciparum V1S (pfcrt 76K) clone was exposed to lumefantrine [158]. The up-regulation of 
pfvp2 suggests that it could be involved in maintaining the H+ balance in the parasite DV and 
to compensate for H+ loss caused by removal of protonated CQ [191]. As described above, 
CQ resistance involves the removal of protonated CQ from the DV. This is likely to cause a 
loss of H+ that needs to be replaced if the DV is to remain acidic. 
1.6.2.5 P. falciparum Na+/H+ exchanger-1 – pfnhe1 
The pfnhe1 protein is believed to be located in the plasma membrane of the parasite [147, 
192]. Though pfnhe1 function has not been fully determined, it has been proposed that pfnhe1 
actively effluxes protons out of the parasite to maintain a pH of 7.4 within the malaria 
parasite [192]. Polymorphisms in pfnhe1 have been associated with different susceptibilities 
to QN [54, 75]. Specifically, >1 DNNND repeat and one DDNHNDNHNND repeat in the 
coding microsatellite ms4760 have been associated with reduced in vitro and in vivo QN 
sensitivity [75, 79, 97]. These pfnhe1 repeats have been associated with changes in the 
cytosolic pH affecting the parasite susceptibility to QN [147]. However, pfnhe1 is not the 
major pH regulator in the parasite [193] and the cytosolic pH was not affected when pfnhe1 
expression was reduced by 50% [194]. Pfnhe1 has also been suggested to play a role in CQ 
resistance [195, 196], but this was subsequently disputed [193, 197]. 
1.6.2.6 P. falciparum multidrug-resistant protein 1 – pfmrp1 
Pfmrp1 is an active transporter located at the plasma membrane of the plasmodium parasite 
[198]. It is thought to be involved in the transport of CQ and QN, out of the cell. In line with 
this, P. falciparum in vitro susceptibility to CQ, QN, artemisinin, piperaquine and primaquine 
increased and CQ accumulated when pfmrp1 function was disrupted [146]. Various pfmrp1 
SNPs and haplotypes have been associated to different responses to CQ, QN, mefloquine, 
pyronaridine, SP and ACTs in Africa, Southeast Asia and Oceania. However, in some 
countries associations were not found as described below. Pfmrp1 H191Y and S437A SNPs 
were previously associated with increased susceptibility to CQ and QN in Southeast Asia 
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 [168] but later no association were found in the same area [199]. Pfmrp1 I876V SNP has 
been associated with reduced susceptibility to CQ (China-Myanmar border), artesunate-
mefloquine (Thai-Myanmar border), and artemether-lumefantrine (Africa) [200-202]. 
However in north-east Myanmar no associations were found to these drugs [203]. Pfmrp1 
F1390I has been associated with reduced in vitro susceptibility to lumefantrine [204] and in 
vivo resistance to artesunate and mefloquine in Cambodia [205]. The R1466K SNP has also 
been associated with recrudescence after treatment with SP [206], however in recent studies 
from Benin and Myanmar no associations were found [184, 203]. 
1.6.2.7 P. vivax chloroquine resistance transporter – pvcrt-o and P. vivax multidrug 
resistance 1 - pvmdr1 
So far no association between mutations in the pvcrt-o and in vivo or in vitro response to CQ 
have been found [119, 207-212]. The pvmdr1 976F allele has been associated with reduced 
susceptibility to CQ and amodiaquine [209, 213] and increased susceptibility to mefloquine 
and artesunate in Thailand, Indonesia and PNG [209, 213-215]. However, the correlation is 
not absolute as P. vivax CQ resistant can show Y976 and 976F parasites can be successfully 
treated [119, 208, 209, 216]. Amplifications of pvmdr1 have been associated with reduced 
susceptibility to amodiaquine, mefloquine and artesunate in Thailand and Myanmar [209, 
210, 213, 217]. However, in Indonesian P. vivax, resistant to the same drugs, no pvmdr1 
amplifications were found [213]. The role of pvmdr1 in P. vivax drug resistance thus remains 
under discussion. 
1.6.3 Antifolates 
1.6.3.1 Dihydrofolate reductase – dhfr and dihydropteroate synthase – dhps 
The dhfr coding region was cloned from P. falciparum in 1987 [218] and the P. vivax gene 
was identified in 1998 [219]. The dhfr genes from both species are ~66% identical and the 
active site regions are strongly conserved [220]. 
The gradual acquisition of resistance associated SNPs (N51I, C58R, S108N and I164L) in 
pfdhfr results in increasing levels of drug tolerance [221]. The triple dihydrofolate reductase 
(pfdhfr) haplotype N51I/C59R/S108N has been associated with SP treatment failure and 
when dihydropteroate synthase (pfdhps) SNPs A437G and K540E are added, highly SP 
resistant P. falciparum are generated [217, 222-225]. 
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 Twenty single nucleotide polymorphisms have been described in P. vivax dihydrofolate 
reductase (pvdhfr) including F57L, S58R, T61M and S117N/T that correspond to codons 50, 
51, 59 and 108 in pfdhfr, respectively [132, 226-228]. Pvdhfr S58R and S117N result in 
decreased binding of PYR [220] and quadruple (F57L, S58R, S117N and I173L) SNPs have 
been associated with SP treatment failure [132, 226, 227]. 
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 2 AIMS OF THE THESIS 
Overall Aim: 
The overall aim was to determine temporal and geographic frequencies of known and 
putative genetic polymorphisms linked to P. falciparum and P. vivax drug resistance after 
exposure to various antimalarial drugs  
Specific aims: 
Paper I: Determine the proportion of chloroquine and sulphadoxine-pyrimethamine 
resistance associated genetic polymorphisms in P. falciparum and P. vivax collected in 
Honduras. 
Paper II: Identify genetic changes in pfvp2 and to describe their prevalence in 8 different 
countries and association with polymorphisms in pfcrt and pfmdr1. 
Paper III: Study the early in vivo selection of genetic markers associated with antimalarial 
drug resistance after repetitive exposure to chloroquine, pyrimethamine or chlorproguanil 
compared with placebo in a previously virtually antimalarial drug naïve area of Liberia 
Paper IV: Determine the temporal and seasonal frequency of genotypes associated with 
reduced susceptibility to chloroquine, artemether-lumefantrine and quinine between 2003 and 
2012. 
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 3 MATERIALS AND METHODS 
3.1 Origin and sample collection 
3.1.1 Honduras 
In Honduras malaria transmission is seasonal and A. albimanus and A. darling are the two 
main vectors that transmit malaria during the rainy and dry seasons, respectively.[229]. 
Honduras contributes approximately 46% of malaria cases in Central America. More than 
6,000 cases were reported in 2012 following an estimated  incidence decrease of >75% since 
2000 [9] The majority of malaria cases are caused by P. vivax and 12-15% are due to P. 
falciparum [9, 230]. 
CQ is recommended for treatment of uncomplicated P. falciparum and P. vivax infection. In 
addition, primaquine is used for treatment of P. falciparum gametocytes and P. vivax 
hypnozoites [231]. These drugs appear to remain effective despite being used for six decades 
and despite the spread of CQ resistant P. falciparum across most of the rest of the world [102, 
232]. 
Filter paper samples for paper I were collected from adults that sought medical attention or 
were referred to the Hospital Escuela in Tegucigalpa between 2004 and 2006, and the 
regional hospitals in Trujillo, La Ceiba and Juticalpa, two primary health centres in Puerto 
Lempira and Iriona and one regional laboratory in Juticalpa during 2009. At the Hospital 
Escuela sample collection was considered to be part of routine malaria surveillance and did 
not involve additional sampling or collection of patient data. At the other health facilities 
patients who sought medical attention and were diagnosed with malaria were invited to 
participate in the study after written informed consent. 
3.1.2 Colombia 
Malaria transmission is endemic/epidemic and unstable throughout the country. Malaria is 
caused mainly by P. vivax (73%) and P. falciparum and occasionally by P. malariae [9, 233]. 
Samples for paper II were culture adapted isolates collected between 2001 and 2005 from 
endemic regions and were provided by Centro Internacional de Entrenamiento e 
Investigaciones Medicas (CIDEIM) in Cali, Colombia. When the samples were collected the 
national drug policy was amodiaquine + SP [233]. 
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 3.1.3 Liberia 
Malaria was holoendemic when the samples were collected [234]. In 1976 (prior to 
deployment of monthly presumptive treatment) the overall parasite prevalence in the study 
area assessed by blood slide microscopy in 2-9 years old children was 82% for P. falciparum, 
39% for P. malariae and 9% for P. ovale [235]. At the time of sample collection the official 
antimalarial drug policy was CQ [126] however, in 1976 the study area was virtually drug 
naïve. 
Samples were collected in 1978 (paper III) and 1981 (paper II) as part of clinical studies in a 
rural area of northern Liberia 25 to 35 km from Yekepa. Four villages, about 5 km from each 
other, were included in study III: Bondi, Baytonwee, Bonah and Kinon. Access to healthcare 
and specifically antimalarial treatment was very limited when the study started in 1976. 
Children 2-9 years old were invited to participate in the study in 1976. Included children were 
given single doses of CQ, CPGN, PYR or placebo every four weeks for two years as follows. 
Bondi: 8-15 mg base/kg dose of CQ. Baytonwee: 1.0-2.0 mg base/kg of CPGN. Bonah: 1.3-
2.5 mg base/kg of PYR. Kinon: 1 or 2 tablets of Vitamin B (placebo). Drug intake was 
supervised by the investigators [234]. After 2 years of monthly presumptive treatment, 
capillary whole blood samples were collected 4-6 weeks after last intake of study drug (i.e. 
from 28th of February to 17th of March, 1978) from all children (n=191) present and still 
included in the study. Samples selected for paper II were from children 2-9 years old from 
Bonah village in 1981. 
3.1.4 Guinea-Bissau 
Malaria is generally considered to be meso or hyperendemic in Guinea-Bissau. The main 
malaria species is P. falciparum (100%) [9]. Malaria is transmitted throughout the year with 
seasonal peaks before and towards the end of the rainy period between June and November. 
The mean annual incidence decreased from 16 per 1000 (1995–1997) to 3 per 1000 in 2007 
and then increased to 26 per 1000 by 2011 and finally decreased to 10 per 1000 in 2012 
[236]. Long lasting insecticide treated bed nets (LLIN) were distributed in 2011 and by 2012 
there was 1 net per 2 people and 97% usage [236]. In June 2008 AL replaced an efficacious 
high dose CQ treatment regime (that was used instead of the officially recommended 25 
mg/kg of CQ) for the treatment of uncomplicated malaria [237-239]. The high dose CQ 
treatment regime consisted of ~75mg/kg as 2-3 daily doses for 5 days [237]. QN remained 
the drug of choice for severe malaria throughout. CQ was also commonly used for home 
treatment of fever presumed to be malaria, at least until the introduction of AL. Paper II was 
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 based on blood samples collected between 2003 and 2004 as part of a clinical trial and paper 
IV was based on all blood samples collected for genotyping from 2003 to 2008 and from 
2010 to 2012 as part of five clinical trials. All trials were conducted within the Bandim 
Health and Demographic Surveillance Site (HDSS). 
The drugs used as part of the studies were CQ or amodiaquine (2001-2004), CQ (2004-2006), 
CQ or AL (2006-2008), dihydroartemisinin-piperaquine or AL (November 2012-to date). As 
part of an effectiveness study (2010-2012) antimalarial drug use was monitored and AL was 
prescribed to 47%, QN to 44%, QN + AL to 9% and CQ to 1% of 799 children with 
uncomplicated malaria. Children with recurrent parasitaemia during study follow up were 
retreated with SP, CQ (50 mg/kg) or AL depending on the study. 
3.1.5 Tanzania 
Malaria is transmitted throughout the year with seasonal peaks during periods of increased 
rain in March-May and October-December. The main malaria species is P. falciparum 
(100%) [9]. Filter paper samples from paper II were collected from children ≤10 years as part 
of a community based cross sectional survey conducted at Fukayosi primary health care 
centre in 2008. The Fukayosi village is located in Bagamoyo district on mainland, Tanzania. 
Artemether + lumefantrine were used as first line treatment in Tanzania during the sample 
collection. 
3.1.6 Iran 
Malaria transmission occurs during the whole year and 90% of the cases are attributed to P. 
vivax and 10% to P. falciparum [9]. Whole blood samples were collected from adults at the 
Chabahar City Public Health Department in the Sistan-Baluchistan province of Iran. The 
study was conducted from April 2001 to March 2002 and the first line treatment was CQ 
according to national guidelines [240]. 
3.1.7 Thailand 
Malaria in Thailand is endemic especially in the forest regions and the border areas. Malaria 
cases are attributed to P. falciparum (40%) and P. vivax (60%) [9]. Thailand’s Western 
border with Burma/Myanmar and eastern border with Cambodia are epicentres of emerging 
antimalarial drug resistance. P. falciparum were collected from clinical cases (adults and 
children) from 2002 to 2008 in Mae Sot, in the Tak Province in west of Thailand and adapted 
for in vitro culture. The isolates were provided by the Shoklo Malaria Research Unit. 
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 Artesunate + mefloquine were used as first line treatment for uncomplicated confirmed P. 
falciparum during sample collection [241]. 
3.1.8 Vanuatu 
Vanuatu is a South Pacific archipelago made up of over 80 islands, each with varying levels 
of malaria. Malaria transmission is perennial but seasonal in intensity [242]. Malaria cases are 
attributed to P. falciparum (32%) and P. vivax (68%) [9]. Blood samples were taken from 
adults and children as part of community-based cross sectional survey in Ambae Island in 
2002 and stored on filter paper. At the time CQ + SP were the first line treatment for 
uncomplicated P. falciparum malaria. 
3.2 Sample selection 
For papers I, III and IV all samples collected Honduras (2004-2006 and 2009), Liberia (1978) 
and Guinea-Bissau (2003-2008 and 2010-2012) were analysed. For paper II, previously 
extracted DNA from fifty randomly selected samples from Colombia (1999-2001), Liberia 
(1981), Guinea-Bissau (2001-2004), Tanzania (2008), Iran (2001-2002) and Vanuatu (2002) 
were selected and all available samples from Honduras (35) and Thailand (49) where were 
analysed.  
3.3 Ethical considerations 
All clinical studies had regional ethical approval as follows: Ethical Review Committee of 
Instituto Cardio Pulmonar in Tegucigalpa, Honduras, Liberian Institute of Biomedical 
Research. National Institute for Medical Research Tanzania (NIMR/HQ/ R.8A/Vol. IX/344) , 
Institute Pasteur in Iran (No. 502) , Ethical Committee of the Faculty of Tropical Medicine, 
Mahidol University, Bangkok, Thailand , Ethical Review Committee of the Centro 
Internacional de Entrenamiento en Investigaciones Médicas (CIDEIM), Cali, Colombia. 
Guinea-Bissau studies were approved by Ethical review board in Bissau, Guinea-Bissau 
(Parecet NCP/N19/2006, 019/DHE/2004, 064/DGSP/2006) and Central Scientific Ethics 
Committee in Denmark (624-01-0042). Studies in Vanuatu were approved by the Ethical 
Committee in Tokyo Women’s Medical University, Tokyo, Japan. Molecular analyses were 
approved by the Stockholm regional ethics board (2005/111-31/1, 2006/1151-31/1, 
2011/832-32/2 and 2013/836-32). 
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 3.4 Molecular Analysis 
3.4.1 Sample storage, DNA extraction and amplification 
Filter papers samples were collected in Honduras, Guinea-Bissau, Tanzania, Iran and 
Vanuatu. Capillary blood samples were collected in Liberia. Samples from Colombia and 
Thailand were culture adapted parasites. Filter papers were stored at room temperature while 
capillary blood was kept at -20◦C. 
DNA was extracted using the following methods: ABI Prism® 6100 Nucleic Acid Prep 
Station (Applied Biosystems, Fresno, CA) according to the manufacturer’s instructions with 
minor modifications [243], QIAamp Blood Mini Kit (QIAgen Biosciences, Germantown, 
MD) and cheelex™ based method. Samples from study III (Liberia 1978) were extracted 
separately from other samples to minimise the risk of contamination Extracted DNA was 
stored at -20◦C. 
3.4.2 Restriction Fragment Length Polymorphism (RFLP) 
Previously described multiplex PCR-RFLP methods were used to identify the following 
SNPs; pfcrt K76T, A220S, Q271E, N326D/S, I356L/T and R371I; pfmdr1 N86Y and 184; 
pfdhfr N51I, C59R and N108T/S and pfdhps S436F/A, G437A and K540E [151, 244-246]. 
Pfvp2 SNPs V405I and P711S were identified using nested PCR amplifications followed by 
restriction. A first set of primers were used to amplify nucleotide 1112 to 2260 of pfvp2. Two 
primer pairs were then used to amplify fragments that included codons 405 and 711. Primers 
were designed using Primer Express software (Applied Biosystems, Fresno, CA, USA) based 
on published sequence of P. falciparum (Gene Bank Accession No. AF283528). Primers and 
reactions conditions details are specified in paper II. All reactions included Taq polymerase 
reaction buffer, magnesium chloride, dNTPs, forward and reverse primer pair and GoTaq® 
DNA polymerase. Restriction enzymes (New England Biolabs) used to analyse SNP’s 405 
and 711 were AseI and DpnI. 
PCR products were resolved on 2% agarose gels (Amresco, Solon, OH). All gels were 
stained with ethidium bromide or GelRedTM (Biotium Inc. Hayward, CA, USA) and 
visualized under UV transillumination (GelDoc®, Biorad, Hercules, Ca, USA). 
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 3.4.3 Sequencing 
Pfcrt 72-76, pfdhfr 16-185, pfdhps 436-632, pfmdr1 1034-1246, pfnhe1 ms-4760 haplotypes 
were amplified using previously described PCR protocols [97, 151, 178, 247, 248]. New 
primers (nucleotides 1484-1929) were designed for a nested PCR amplification for 
identification of the pfvp2 K582R allele. Primers and detailed reaction conditions are 
specified in paper II. 
Previously described nested PCRs were used to amplify codons 917 to 1118 of pvmdr1 and 
codons 1 to 238 of pvdhfr [133, 209]. PCR products were purified and sequenced 
commercially (Macrogen Inc. Seoul, Korea). 
The Sequencher ™ software version 4.6 (Gene Codes Corporation, Ann Arbor, MI) was used 
for sequence analysis. The P. falciparum 3D7 clone sequence obtained from the NCBI 
database was used as references for pfcrt (Accession no. NC_004328), pfmdr1 (Accession no. 
XM_001351751.1), pfvp2 (Accession no. AF283528), pfdhfr (Accession no. 
XM_001351443.1) pfdhps (Accession no. XM_001349382.1) and pfnhe1 (Accession no. 
XM_001349726). Pfnhe1 ms4760 sequences were also compared with previously described 
isolates and clones [97, 249]. For pvdhfr the P. vivax ARI/Pakistan isolate sequence (Gen-
Bank accession no. X98123) and for pvmdr1 the P. vivax Sal-1 isolate sequence (Gen-Bank 
accession no. AY618622) were used as references. 
3.4.4 Real-Time PCR 
Pfmdr1 and pvmdr1 copy numbers were determined using real time PCR (ABI Prism® 7000 
Sequence Detection System) as previously described [62, 210]. All samples were run in 
triplicate. For pfmdr1 3D7, D10 and K1 clones were used as single copy calibrators and FCB 
and Dd2 were multiple copy controls. Pvmdr1 single and double copy calibrators were 
created by the insertion of pvmdr1 nucleotides 2751-3354 and pvbtubulin nucleotides 860-
1056 in the pCR2.1 vector using the TOPO TA-cloning kit (Invitrogen, Carlsbad, CA) at 1:1 
and 2:1 proportions, respectively. The sample copy numbers were calculated using a 
comparative threshold method (∆∆Ct). Copy number >1.6 and copy number >2.6 were 
defined as 2 and 3 copies of pfmdr1, respectively. Assays were repeated if the following 
results were obtained: copy number 1.3-1.6 and 2.3-2.6 or Ct value >35 or standard deviation 
value >0.5 
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 3.5 Statistics 
Data for papers I to III were entered, validated and analysed on Microsoft Excel 2003. Allele 
proportions were calculated by dividing the number of samples with a certain allele by the 
number of samples with an identifiable allele at that position. Thus mixed infections 
contributed to the proportion of both alleles. Associations were determined using Fishers 
Exact test using StataCorp 12. 
Data for paper IV were entered on EpiData or Microsoft Excel and transferred to Stata Corp 
12 for analyses. As above SNP frequencies were calculated as the number of samples with a 
certain allele. Haplotype frequencies were calculated after excluding mixed infections. Yearly 
and seasonal changes of allele and haplotype frequencies were estimated using logistic 
regression with bootstrapping (100 repeats) with year or month as continuous covariate and 
the earliest time point as baseline. For calculation of seasonal changes, February was the 
earliest time point as the high transmission season ends in January. Parasite densities and age 
were estimated and compared using quantile regression with bootstrapping (100 repeats).  
For paper II and IV, linkage disequilibrium was calculated as a correlation coefficient 
between pairs of loci after excluding mixed infections. For paper II, absolute linkage was 
indicated by a value D=1 whereas D=0 indicated no linkage. For paper IV a correlation 
coefficient (r) of 1 indicated absolute correlation, 0 indicated no correlation and -1 total 
negative correlation. 
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 4 RESULTS AND DISCUSSION 
4.1 Genetic Polymorphisms in P. falciparum 
4.1.1 P. falciparum chloroquine resistance transporter  
4.1.1.1 Pfcrt 72-76 haplotypes 
The pfcrt 72-76 haplotype was determined in samples from Honduras (30), Colombia (50), 
Liberia (50), Guinea-Bissau (50), Tanzania (50), Iran (50), Thailand (49) and Vanuatu (38) 
representing different origins of CQ resistance in papers I and II. In paper III, the pfcrt 72-76 
haplotype was determined in 178 samples after repeated antimalarial exposure in a previously 
virtually antimalarial drug naïve area of Liberia. The haplotypes found and the frequencies in 
the various countries are shown in Figure 2. Three (of 5) different pfcrt 72-76 CQ resistant 
haplotypes were found, specifically, CVMNT from Colombia,  SVMNT from Papua New 
Guinea and CVIET from Thailand ( which subsequently spread to Africa) [59]. 
 
Figure 2.- Pfcrt 72-76 haplotypes and frequencies. Infections with mixed pfcrt 72-76 haplotypes were 
excluded. One pfcrt 72-76 CVIET haplotype was found in Liberia.  
All 30 samples from Honduras carried the pfcrt CVMNK haplotype that is linked to CQ 
sensitivity (paper I and II). The results are in line with continued efficacy to CQ seen in vitro 
and in vivo [232, 250, 251]. This was, to our knowledge, the first report of these haplotypes 
from Mesoamerica. The pfcrt CVMNK haplotype was also found in 227/228 samples 
collected in Liberia in 1978 (paper III) and 1981 (paper II). Finding the CVMNK haplotype 
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 in Liberia was in line with in vivo and  in vitro CQ sensitivity results found at the time of 
sample collection [234, 252, 253]. The CVMNK haplotype found in Liberia, was the same as 
that found in 226/226 samples from Gambia collected in 1984 [254] and in CQ sensitive 
parasites in Guinea-Bissau [239] indicating that this was the wild type haplotype in West 
Africa before CQ resistance arrive to the area. 
A single sample carrying pfcrt CVIET was detected in Liberia in 1978 after treatment with 
CQ (paper III). Though this pfcrt CVIET might have been imported from Southeast Asia it 
did not show the additional SNPs at codons 220, 271, 326, 356 and 371 usually present in 
Southeast Asian pfcrt [255]. It is thus probable that pfcrt 72-76 CVIET arose in the study area 
after intermittent treatment with CQ for only two years. A recent study described how 
resistance associated pfcrt SNPs accumulated in an ordered fashion controlled by a balance 
between improved CQ transport versus loss of fitness / function induced by mutations [155]. 
Having CVIET alone with no other SNPs in pfcrt only resulted in a low increase of the ability 
to transport CQ and hence to confer resistance. Thus CVIET might have developed in Liberia 
but it probably did not provide a selective advantage in this holoendemic area accounting for 
the haplotype not becoming widespread as indicated by all samples from Liberia collected in 
1981 only having the CVMNK haplotype. In line with this, CQ resistant P. falciparum took 
approximately 12 years to develop in Southeast Asia and South America [31] from where it 
was eventually imported to Africa. Nevertheless, the possibility that this haplotype seems to 
have arisen de novo is intriguing and warrants further study to confirm this. 
4.1.1.2 Pfcrt K76T 
High pfcrt K76 proportions were found in Honduras (30/30 [100%]) and Liberia (227/ 228 
[99.5%]) as shown in papers I to III, in Guinea-Bissau (614/766 [80%]) from 2003 to 2007 
and in Tanzania (33/50 [66%]) as shown in papers II and IV. Pfcrt 76T proportions were high 
in Iran (49/50 [98%]), Vanuatu (38/38 [100%]), Colombia (50/50 [100%]) and Thailand 
(49/49 [100%]) as shown in paper II. 
The ~100% pfcrt K76 frequency in Honduras and Liberia was in line with continued CQ 
efficacy in both countries [234, 256]. Surprisingly and for principally unknown reasons P. 
falciparum in Honduras therefore remain susceptible to CQ despite six decades of use, the 
worldwide spread of CQ resistance and the sporadic occurrence of CQ resistant P. falciparum 
in Nicaragua [257]. The high pfcrt K76 proportion in Guinea-Bissau concurrently with 
continued CQ use was also surprising but probably due to the routine use of high doses of CQ 
(~75mg/kg as 2-3 daily doses for 5 days ) as discussed previously [258]. Briefly, higher 
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 concentrations of CQ can effectively treat P. falciparum with pfcrt 76T. Furthermore pfcrt 
76T causes a loss of fitness as discussed above. Thus pfcrt 76T did not provide a survival 
advantage when high CQ doses were routinely used and therefore did not accumulate. In line 
with this pfcrt K76 (1800 P. falciparum/µl) was associated with a significantly higher 
(p=0.005) day 0 parasite density compared to pfcrt 76T (15120 P. falciparum/µl) in Guinea-
Bissau. Further evidence of the cost to fitness caused by pfcrt 76T is the rapid decrease of 
pfcrt 76T and increase of pfcrt K76 when CQ pressure decrease as seen in The Gambia and 
Malawi [259, 260]. Most probably the high pfcrt 76K in Tanzania was similarly an effect of a 
change of treatment policy from CQ to AL 7 years prior to sampling. Considering this loss of 
fitness and the use of artesunate + mefloquine it is interesting to note that the pfcrt 76T 
prevalence was 100% in Thailand where CQ resistance developed de novo unlike Africa 
where CQ resistance was imported. The high pfcrt 76T frequencies in Iran, Vanuatu and 
Colombia were on the other hand as expected given that CQ or AQ were used as first line 
treatment when samples were collected. 
 
Pfcrt K76T frequencies were determined in 1806 children aged less than 15 years with 
uncomplicated P. falciparum malaria between 2003 and 2012 in Guinea-Bissau (Figure 3) as 
part of study IV. The pfcrt K76 frequency decreased from ~80% (2003-2007) to 67% (2008-
2012) (p<0.001). Concurrently, the pfcrt 76T frequency increased significantly (p<0.001) 
between 2007 and 2012. In more detail, the pfcrt 76T frequency gradually increased from 
25% (10/40) in 2007 to 57% (195/345) in 2011 and then appeared to decrease to 34% 
(41/121) in 2012. The annual median age increased from 5 years and 8 months to 10 years 
between 2003 and 2012 (p<0.001). The increased pfcrt 76T and decreased pfcrt K76 
frequencies following the introduction of AL in 2008 contradicted expectations as pfcrt K76 
has been associated with reduced susceptibility to lumefantrine and has been selected for after 
treatment with AL [183, 238, 261]. Furthermore, pfcrt 76T has, as discussed above, been 
associated with a fitness cost. 
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Figure 3.- Pfcrt K76T allele frequencies in children aged less than 15 years attending the Bandim health 
centre, Guinea-Bissau between 2003 and 2012. Pfcrt 76T frequency increased to 57% between 2007 and 
2011 (p<0.001) and then decreased to 34% in 2012 (p<0.001). 
Between 2010 and 2012 QN was prescribed to 44% of children diagnosed with P. falciparum 
malaria [236]. Several studies have linked pfcrt 76T to decreased QN susceptibility [168, 
262-264]. In line with this, the pfcrt 76T frequency was higher amongst recrudescing P. 
falciparum compared to day 0 after treatment with QN in Guinea-Bissau [236]. Furthermore, 
pfcrt 76T increased from an average 37% (50/136) during the low transmission period 
(February to July), to 55% (69/126) at the end of the high transmission period (December, 
p=0.03) between 2008 and 2012 as shown in Figure 4. The accumulation of pfcrt 76T 
indicates that pfcrt 76T conferred a selective advantage as drug pressure increased. 
Thus is seems highly probably that the increased 76T frequency was due to QN use. 
Interestingly this was not seen when high dose CQ was used indicating that 76T provided a 
greater selective advantage when QN was used compared to when high dose CQ was used. A 
possible explanation is that sub-therapeutic doses of QN were probably used. QN has 
traditionally been prescribed as a short 3 day treatment in Guinea-Bissau [265] and this 
appeared to be common between 2010 and 2012 as well.  
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Figure 4.- Monthly pfcrt K76T allele, frequencies between 2008 and 2012 in Guinea Bissau. Pfcrt 76K 
possibly decreased from an average 74% (100/136) during the low transmission period (February to July) to 
59% (74/126) in December (p=0.05). 
Alternative explanations for the accumulation of pfcrt 76T include selective pressure by AL. 
However, a study completed in 2008 indicated that AL selected pfcrt K76 in Bissau as 
elsewhere suggesting that this is unlikely [238, 261]. Continued CQ use might also select for 
pfcrt 76T. However, based on prescription data collected 2010-2012 and informal 
questioning, CQ is hardly used anymore [266]. Furthermore, if CQ was the driving force, a 
novel lower and less efficacious CQ dose compared to that routinely used in the past would 
have had to have been used. Increased pfcrt 76T frequency could also be the result of 
selection after the 2007 bottleneck event (when malaria drastically decreased) due to better 
inherent fitness or a selective advantage in older children. For example older children may be 
more likely to self-medicate with CQ at home prior to seeking care at Bandim Health Centre. 
However, SNP frequencies did not vary with age and proxies for fitness such as lower 
parasite density and lower pfcrt 76T frequency during the low transmission period suggest 
that pfcrt 76T was associated with a fitness cost - not benefit. 
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 4.1.2 P. falciparum multidrug resistance 1  
4.1.2.1 Pfmdr1 N86Y 
All samples (30/30) from Honduras (paper I) and all Liberian samples (161/161) collected in 
1978 (paper III) carried pfmdr1 N86. Amongst the 47 samples from Liberia collected in 1981 
one had pfmdr1 86Y and one had mixed pfmdr1 N86 + 86Y (Paper II). Detailed pfmdr1 
N86Y frequencies from papers I to IV are shown in Table 1. 
Country pfmdr1 N86 86Y 
Liberia 1978 191/191 (100%) 0/191 
Liberia 1981 46/47 (98%) 2/47 (4%) 
Guinea-Bissau 2003-2007a 564/770 (73%) 332/770 (43%) 
Guinea Bissau 2007-2010 682/880 (77%) 274/880 (31%) 
Tanzania  34/50 (68%) 16/50 (32%) 
Iran  13/50 (26%) 37/50 (74%) 
Thailand  49/49 (100%) 0/49 
Vanuatu  0/32 32/32 (100%) 
Honduras 30/30 (100%) 0/30 
Colombia  50/50 (100%) 0/50 
Table 1 Pfmdr1 N86Y frequencies in data pooled from studies I-IV 
aFifty samples randomly selected collected between 2003-2004 were used for paper II 
Pfmdr1 N86 was determined in 1650 samples from Guinea-Bissau collected between 2003 
and 2012 in paper IV. Pfmdr1 N86Y allele frequencies did not change significantly before 
2007. Pfmdr1 N86 increased significantly (63% to 83%, p<0.001) and pfmdr1 86Y decreased 
significantly (48% to 34%, p<0.001) between 2007 and 2012, as shown in figure 5. 
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Figure 5.- Pfmdr1 N86Y allele frequencies in children aged less than 15 years attending the Bandim health 
centre, Guinea-Bissau between 2003 and 2012. 
Pfmdr1 86Y has previously been associated with CQ and amodiaquine resistance in vitro and 
in vivo [172, 182, 245, 267-271]. However, some studies have contradicted this association 
[272, 273]. Nevertheless there is a consensus that pfmdr1 enhances CQ resistance [151, 185, 
274] and or compensates for loss of fitness in P. falciparum with pfcrt 76T [275, 276]. The 
high proportion of pfmdr1 N86 found together with pfcrt K76 in Liberia (paper II and III) 
indicates that KN was the wild type haplotype. Two samples collected in 1981 in Liberia 
were found to have pfmdr1 86Y. Similar low frequencies of pfmdr1 86Y (5/132) were found 
in 1984 in The Gambia [254]. This is to our knowledge the earliest report of pfmdr1 86Y in 
West Africa and together with the Gambian data it shows that pfmdr1 86Y occurred in West 
Africa prior to the spread of CQ resistance. Both Liberian samples were from the village in 
which monthly CQ was previously administrated and where a single sample with pfcrt 
CVIET was found. Though 86Y may have occurred naturally it is also possible that 86Y was 
an early response to CQ exposure. 
In line with previous reports linking pfmdr1 86Y to enhanced CQ resistance [185, 274], high 
proportions were found in Vanuatu and Iran were pfcrt 76T frequencies were ~100% and CQ 
was first line treatment for uncomplicated P. falciparum malaria at the time of sample 
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 collection. High pfmdr1 86Y frequencies in Iran and Vanuatu were also in line with reports of 
CQ failure in these countries [277, 278]. However, without data from the time before CQ 
resistance it is not possible to draw any conclusions. Pfmdr1 86Y did not accumulate between 
2003 and 2007 in Guinea-Bissau suggesting that 86Y just as 76T did not provide a significant 
selective advantage when high dose CQ was used in Guinea-Bissau. 
4.1.2.2 Pfmdr1 N86Y and pfcrt K76T haplotypes in Guinea-Bissau. 
Further analysis showed that pfcrt 76 + pfmdr1 86 KN (p=0.002) and KY (p<0.001) 
haplotypes decreased significantly whereas TY remained stable at ~10% between 2003 and 
2012 in Guinea-Bissau. The TN frequency was ~10% between 2003 and 2007 but then 
increased to 27% by 2012 (p=0.001). Frequencies of pfcrt K76Y + pfmdr1 N86Y haplotypes 
are presented in table 2. Median parasite densities were significantly higher with pfcrt 76 + 
pfmdr1 86 KN (18000 P. falciparum/µl, p=0.008) and KY (18400 P. falciparum/µl, p=0.004) 
compared to TY (14640 P. falciparum/µl) but there was no significant difference between 
KN or KY compared to TN (15840 P. falciparum/µl). 
As discussed above QN may have selected pfcrt 76T. In line with this, the increase of pfcrt 
76T + pfmdr1 86N between 2007 and 2012 in Guinea-Bissau could be due to direct selection 
by QN. However, decreased QN susceptibility has more often been linked with the TY 
haplotype [168, 264]. The discrepancy may be due to the probably multigenic basis of QN 
resistance [75, 168]. Alternatively, the TN haplotype is inherently fitter compared to TY, at 
least in Guinea-Bissau. The significantly lower parasite density found with TY but not with 
TN compared to KN or KY might support this, assuming that day 0 parasite density is a 
proxy for inherent parasite fitness. The improved fitness of TN compared to TY may also 
contribute to the fixed pfcrt 76T + pfmdr1 N86 haplotype seen in Colombia and Thailand. 
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 Year Pfcrt K76T + pfmdr1 N86Y haplotypes 
 Total Number KNa KYa TNb TY 
2003 254 56% (142) 23% (59) 9% (24) 11% (29) 
2004 129 56% (72) 21% (27) 9% (11) 15% (19) 
2005 139 65% (91) 14% (20) 10% (14) 10% (14) 
2006 65 63% (41) 15% (10) 11% (7) 11% (7) 
2007 36 47% (17) 31% (11) 11% (4) 11% (4) 
2008 121 46% (56) 23% (28) 22% (27) 8% (10) 
2010 263 50% (132) 10% (26) 26% (68) 14% (37) 
2011 263 46% (122) 12% (31) 29% (75) 13% (35) 
2012 89 54% (48) 10% (9) 27% (24) 9% (8) 
Table 2. Pfcrt K76T and pfmdr1 N86Y haplotype frequencies between 2003 and 2012 
amongst children diagnosed with P. falciparum malaria at the Bandim health centre. 
a KN (p=0.002) and KY (p<0.001) frequencies decreased over time. b TN increased 
between 2007 and 2012 (p=0.001). 
4.1.2.3 Pfcrt K76T and pfmdr1 N86Y / F184Y / D1246Y haplotypes in Guinea-Bissau 
Pfmdr1 86 + 184 NF frequency increased significantly from 39% (87/223) in 2003 to 66% 
(33/50) in 2012 (p=0.004) whilst YF decreased significantly (p<0.001) from 37% (82/223) to 
10% (5/50) in the same period as shown in table 3. The pfmdr1 1034, 1042 and 1246 
haplotype was SND in 137/138 samples between 2003 and 2004 and 315/316 in 2011. 
Year Pfmdr1 N86Y + pfmdr1 F184Y haplotypes 
 Total number NFa NY YFb YY 
2003 223 39% (87) 22% (49) 37% (82) 2% (5) 
2010 221 52% (116) 25% (55) 19% (41) 4% (9) 
2011 246 46% (114) 27% (66) 22% (54) 5% (12) 
2012 50 66% (33) 24% (12) 10% (5) 0% (0) 
Table 3.- Pfmdr1 N86Y and pfmdr1 F184Y haplotype frequencies between 2003 and 
2012 amongst children diagnosed with P. falciparum malaria at the Bandim health 
centre. a NF frequency increased (p=0.004). bYF frequency decreased over time 
(p<0.001). 
Pfcrt 76 + pfmdr1 86 + pfmdr1 184 haplotypes were determined in 219, 200, 191 and 42 
samples in 2003, 2010, 2011 and 2012, respectively. The KNF frequencies did not change 
significantly (p=0.8), KYF decreased from 24% to 7%, 11% and 7%, respectively (p<0.001), 
TNF increased from 7% to 17%, 17% and 21%, respectively (p=0.002) and TNY increased 
from 3% to 10%, 13% and 7% (p=0.001). 
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 Reduced susceptibility to lumefantrine and recurring parasites after treatment with AL have 
been linked to pfmdr1 N86, the pfmdr1 86+184+1246 NFD haplotype and pfmdr1 
amplifications in addition to pfcrt K76 [61, 183, 238, 261, 279-282]. Increased pfmdr1 86N 
and pfmdr1 86+184 NF haplotype frequencies following the introduction of AL are in line 
with these previous observations. As pfmdr1 D1246 was fixed at ~100% frequency in our 
study area the selection of pfmdr1 86+184 NF actually represented a selection of the pfmdr1 
NFD haplotype that has been linked to a 15 fold higher in vivo AL tolerance [279]. As 
discussed above QN probably selected the pfcrt 76 + pfmdr1 TN haplotype. As both the pfcrt 
76 + pfmdr1 86 + 184 TNF and TNY haplotypes increased it seems likely that neither pfmdr1 
184 allele conferred a selective advantage against QN. The increased NF frequency was 
therefore more likely driven by AL than QN. 
4.1.2.4 Pfmdr1 copy number (CN) variation 
Pfmdr1 CN variation was determined in 320 samples from 8 different countries in paper II. 
One pfmdr1 copy was found in Liberia (30/30), Tanzania (46/46), Iran (36/36), Thailand 
(26/49), Vanuatu (9/9), Honduras (28/28) and Colombia (44/44). Two (14/49) and three 
(5/49) copies of the pfmdr1 gene were present in samples from Thailand. In Guinea-Bissau 
(paper II and IV) one gene copy was found in 1635 samples, 1.5 copies were found in two 
samples and one sample had two copies. 
Increased pfmdr1 CN has been linked to reduced susceptibility to artemisinin derivatives, 
lumefantrine, piperaquine and mefloquine as well as to artesunate + mefloquine treatment 
failure [166, 283-285]. Not finding pfmdr1 CN variation in Honduras, Colombia, Liberia, 
Iran, Vanuatu and Guinea-Bissau before 2008 was therefore consistent with expectations as 
they were not using antimalarial drugs that select for increased pfmdr1 CN when the samples 
were collected. The high frequency of >1 CN in Thailand is in line with previous reports and 
has been discussed elsewhere [65, 204]. It was encouraging that only 1 pfmdr1 copy was 
found in Tanzanian samples despite AL being used there since 2001. Finding 3 samples with 
increased CN in Guinea-Bissau could be due to introduction of AL there. However, the first 
sample with two copies was detected in 2008 and the frequency did not subsequently increase 
suggesting that increased CN did not provide P. falciparum with a great selective advantage 
in Guinea-Bissau. Alternatively, finding so few samples with increased copy number might 
well be within the margin of error when doing PCRs suggesting that none exist in Bissau. 
Either way P. falciparum with multiple pfmdr1 copies have not become widespread in Bissau 
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 or Tanzania contrary to the situation in Ghana where relatively high frequencies were 
recently reported [281]. 
4.1.3 P. falciparum V-type H+ pyrophosphatase 
Frequencies of pfvp2 V405I, K582R and P711S were determined in 8 different countries as 
shown in table 4. The most striking result was the lack of variation of the pfvp2 alleles 
studied. Only 26 SNPs in 20 samples were found among 344 samples collected in 8 countries 
with varying origins and proportions of CQ resistant P. falciparum at the time of blood 
sampling. The results thus suggest that the parts of the pfvp2 gene that were analysed are 
conserved. 
Country 
Pfvp2 
405I 582R 711S 
Liberia 3/48 1/48 4/49 
Guinea Bissau 3/50 1/50 3/50 
Tanzania 0/49 1/50 2/48 
Iran 1/50 1/50 1/50 
Thailand 1/49 0/49 1/49 
Vanuatu 0/31 0/32 0/38 
Honduras 2/30 0/30 1/30 
Colombia 0/46 0/46 0/50 
Table 4 – Frequencies and geographical distribution of polymorphisms in pfvp2. 
Despite the lack of variation the pfvp2 405+582+711 VKP haplotype was found to be 
associated with pfcrt 76T (p=0.007) as shown in table 5. Furthermore, linkage disequilibrium 
analysis also showed that pfvp2 VKP haplotype was linked with pfcrt 76T (D=0.5). As pfcrt 
76T is essential for CQ resistance these results suggest that the pfvp2 405V, 582K and 711P 
haplotype is associated with CQ resistance. Pfvp2 up-regulation has been shown to occur in 
P. falciparum with the CQ resistant allele pfcrt 76I but not with the CQ sensitive allele 76K 
under CQ pressure [191]. This was proposed to be due to a need for increased H+ transport 
into the parasite DV to compensate for H+ loss when protonated CQ was transported out 
[153, 154]. Assuming that pfvp2 functions as suggested our results indicate that in P. 
falciparum with the pfcrt 76T genotype the pfvp2 405V, 582K and 711P haplotype provides 
the most efficient H+ pump. 
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 pfvp2 Pfcrt pfmdr1 
K76 76T N86 86Y 
V405 95% (138/145) 99% (198/201)a 97% (235/242) 98% (99/101) 
K582 98% (143/146) 99% (199/200)b 99% (240/243) 99% (101/102) 
P711 95% (138/146) 99% (204/207)c 96% (236/246) 99% (103/104) 
VKP haplotype 90% (131/145) 97% (191/196)d 93% (224/240) 97% (95/98) 
405I 5% (7/145) 1% (3/201) 3% (7/242) 2% (2/101) 
582R 2% (3/146) 1% (1/200) 1% (3/243) 1% (1/102) 
711S 5% (8/146) 1% (3/207) 4% (10/246) 1% (1/104) 
I and/or R and/or S*  10% (14/145) 97% (5/196) 7% (16/240) 3% (3/98) 
Table 5. - The frequency of pfvp2 alleles in P. falciparum with varying pfcrt K76T and pfmdr1 N86Y 
alleles. a V405 occurred non significantly more often with 76T P=0.1; b K582 occurred non 
significantly more often with 76T P=0.3; c P582 occurred non significantly more often with 76T 
P=0.06; d The pfvp2 V405 + K582 + P711 haplotype was significantly more common with pfcrt 76T 
(P=0.007); * i.e. not the VKP haplotype. Patients with both pfcrt K76 and 76T and patients with both 
pfmdr1 N86 and 86Y were excluded. 
Compared to all other countries the proportion of patient samples with any of pfvp2 405I, 
582R and/or 711S was significantly more common in the following countries (table 4); 
Liberia (P=0.01), African countries (Liberia + Guinea-Bissau + Tanzania, P=0.004) and 
countries where CQ resistance had not been described at the time of blood sampling (Liberia 
+ Honduras, P=0.001) compared to the other countries studied. In line with these findings 
there was also an association between samples with any of pfvp2 405I, 582R and/or 711S 
with pfcrt 76K (P=0.007) and the pfcrt 76K + pfmdr1 86N haplotype (P=0.002). 
Furthermore, pfvp2 405I and/or 582R and/or 711S (i.e not the VKP haplotype) were linked 
with pfcrt 76K (D=0.5). Finding pfvp2 405I, 582R and/or 711S alleles in CQ sensitive 
settings in both Africa and the Americas suggests that there was a larger variation in the 
pfvp2 genome prior to the spread of CQ resistance supporting the association between pfvp2 
and CQ resistance. 
Fourteen of 20 patient samples with pfvp2 405I, 582R and/or 711S came from African 
countries of which, 11/20 came from West Africa. This might suggest that the association 
between pfvp2 and pfcrt is incidental possibly due to geographical variation. However the 
pfvp2 SNPs were also linked to pfcrt 76K in Tanzania. An alternative explanation for the 
relatively common occurrence in Africa is that CQ resistance had not reached Liberia at the 
time of sampling and the proportion of CQ resistant P. falciparum had remained relatively 
low ~25% in Guinea-Bissau [258]. There had thus been less selective pressure on pfvp2 in 
these two countries and P. falciparum had not passed through the parasite population bottle 
neck of spreading CQ resistance. Despite the link between pfvp2 V405 + K582 +P711 and 
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 pfcrt 76T very little variation was found in the pfvp2 gene, therefore the results should be 
interpreted with caution. 
4.1.4 P. falciparum Na+/H+ exchanger-1 
Eight of the 114 previously described pfnhe1 variants [97, 249] and 47 novel ms4760 
variants were found in 156 samples collected in Liberia in 1978 (paper III). Similar high 
diversity has previously been reported from different African countries but not in samples 
from Asia [249, 286]. Finding higher diversity in Africa might be linked to greater malaria 
endemicity of P. falciparum. Distribution of DNNND and DDNHNDNHNND repeats in 
Blocks II and V were similar in all villages. Having more than one DNNND repeat and one 
DDNHNDNHNND repeat in the coding ms4760 of pfnhe1 and specifically the ms4760-1 
haplotype that has 2 x DNNND and 1 x DDNHNDNHNND have been associated with QN 
resistance in vitro and in vivo in some studies but not in others [75, 97, 249, 286]. Though 
QN was not used in the Yekepa area at the time of this study the frequency of pfnhe1 
ms4760-1 (26%) was similar to the frequency found at day 0 in a recent study in Mali 
where ms4760-1 was associated with QN resistance [97]. Furthermore, the number and 
frequencies of DDNHNDNHNND repeats in this study were similar to data found in 393 
clinical isolates recently reported from Senegal [286]. Despite the geographic separation, 
the similarity to that found in Liberia in 1978 , prior to a drug selective pressure, suggests 
that ms4760-1 did not play a significant role in the emergence of resistance in West Africa 
over subsequent years. 
4.1.5 Polymorphisms associated with antifolate resistance: P. falciparum 
dihydrofolate reductase and P. falciparum dihydropteroate synthase. 
Pfdhps and pfdhfr SNPs were analysed in samples from Honduras collected between 2004 
and 2006 and in 2009 (paper I) and in samples from Liberia collected in 1978 (paper III). 
The PYR resistance associated pfdhfr 108N and sulphadoxine resistant associated 613S 
were found in 38% (65/169) and 10% (14/135) of Liberian samples. No other SP resistance 
associated polymorphisms were found. Both pfdhfr 108N and pfdhps 613S were 
significantly lower in the village using PYR (1/46 and 0/38 respectively) compared to the 
other villages as presented in table 6. All Honduran samples (30/30) had haplotypes pfdhfr 
N51 + C59 + S108 and pfdhps A437 + K540 linked to sensitivity to SP. 
The high frequency of pfdhfr 108N in the placebo village indicates that 108N was a 
naturally occurring allele prior to the introduction of antifolates for the treatment of malaria 
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 in Liberia in 1978. Similarly, pfdhfr 51I, 59R, 108N SNPs were found in 9/66 samples 
collected in The Gambia in 1984 prior to SP use [254]. Contrary to our expectations pfdhfr 
108N was not selected in the PYR village despite development of in vivo resistance to PYR 
within a year of initiating monthly intermittent presumptive therapy [234]. This indicates 
that there was an alternate mechanism of PYR resistance as has previously been suggested 
[287, 288]. Furthermore, the 108N did not provide a selective advantage in the presence of 
this alternate mechanism but possibly the opposite. Amplifications of the pfdhfr or GTP-
cyclohydrolase (gch1) genes have been linked to PYR resistance in the past [289, 290]. 
Gene amplifications could have occurred in Liberia and might thus constitute an early 
method of drug resistance in line with the correlation between pfmdr1 amplifications and 
drug resistance to mefloquine and artemisinin derivatives [283]. An alternative mechanism 
of PYR resistance might be a greater influx of folate into the parasite as has been suggested 
to be mediated by pfmrp1 1466K [206]. However, in Liberia only pfmrp1 R1466 was 
found. PYR is not likely to directly exert a selective effect on pfdhps yet the frequency of 
pfdhps 613S (that is related to sulphadoxine resistance) was lower in the PYR treated 
village (0/38). Perhaps this represents an indirect effect of selection of other genes. 
Village 
Pfdhfr Pfdhps 
S108 108N 108S+N A613 613S 
Chlorproguanil 21/39 (54%) 17/39 (45%) 1/39 (3%) 29/32 (91%) 3 (9%) 
Pyrimethamine 45/46 (98%) 1/46 (2%)b 0 38/38 0c 
Chloroquine 21/39 (54%) 18/39 (46%) 0 19/26 (73%) 7(27%) 
Placebo a 15/45 (33%) 29/45 (65%) 1/45 (2%) 35/39 (90%) 4 (10%) 
Table 6. Allele frequencies at resistance associated pfdhfr codon 108 and pfdhps codon 613 from 
samples collected in Liberia in 1978.   Resistance associated alleles are shown in bold.     a Vitamin B. 
b The frequency of samples with the resistance associated pfdhfr 108N was lower in the 
pyrimethamine treated village when compared with separate and pooled frequencies from the other 
villages (P<0.001). c The frequency of samples with the resistance associated pfdhps 613S was lower 
in the pyrimethamine treated village compared to pooled frequencies from the other villages (P<0.01) 
and the village using CQ (P=0.001), but the differences were not significant compared to the villages 
using chlorproguanil (P=0.09) or placebo (P=0.12). 
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 Finding no SNPs associated with SP resistance in Honduras indicates that P. falciparum 
remained sensitive to SP. In line with this antifolates were not previously used as CQ 
remains effective for the treatment of uncomplicated malaria in Honduras. However, SP 
was recently recommended as the second line treatment for uncomplicated malaria in 
Honduras and given the rapid development of SP resistance in the past continued 
monitoring would be worthwhile. Furthermore, the lack of resistance associated SNPs in 
Honduras indicates that artemisinin based treatment combinations containing SP could be 
used if Honduras wishes to change to an ACT. However, the results from Liberia presented 
above caution against only relying on genotyping to monitor for drug resistance. 
4.1.6 CQ and SP resistance in imported malaria in Honduras. 
In Paper I two patients with imported malaria that most probably contracted P. falciparum on 
a Pacific Island and West Africa were included. The patient from the Pacific Island had P. 
falciparum with pfcrt 72-76 SVMNT, pfmdr1 86Y, pfdhfr 51I + 59R+ 108N and pfdhps 
A437 + K540 haplotypes. The patient from West Africa had P. falciparum with pfcrt K76, 
pfmdr1 86Y, pfdhfr 51I + 59R+ 108N and pfdhps A437/437G + K540 haplotypes. These two 
patients highlight the risk of importing drug resistance to Honduras. La Moskitia, from where 
90% of P. falciparum cases of the country are reported is known to be used for drug 
trafficking from South America [291]. Commonly smugglers come by boat or aeroplane 
presumably from Colombia. It is not difficult to envisage resistant P. falciparum also being 
imported this way. The risk of resistant genes crossing over into local P. falciparum is thus 
probably highest here. Yet this has as yet not happened according to the latest survey 
conducted in 2011 [256]. Furthermore, neighbouring Nicaragua recently reported the 
presence of P. falciparum with the CQ resistant pfcrt CVIET haplotype and pfdhfr 51I + 59R 
and/or 108N and pfdhps 437G SP resistant SNPs in 3/49 samples during a clinical trial 
conducted in 2005 [257]. In a follow up survey in Nicaragua in 2011 no SP resistant SNPs 
were present. Considering this, it is worth noting that malaria is often diagnosed clinically in 
Honduras and that it is then treated presumptively with primaquine (0.25mg/kg) for five days 
in addition to CQ. Primaquine reduces gametocyte carriage time thus reducing transmission 
and it is certainly possible that this has contributed to stop resistant P. falciparum from 
becoming established [292, 293]. 
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 4.2 Polymorphism in P. vivax 
4.2.1 P. vivax multidrug resistance gene 1. 
Proportions of pvmdr1 Y976F and F1076L are presented in table 7. In paper I we found 
pvmdr1 976F in 7/41 (17%) samples with P. vivax. These results might indicate a degree of 
CQ tolerance but probably not resistance in Honduras [209, 217, 294]. In line with this, an 
in vivo evaluation conducted in Honduras (1998-2000) found that 73/73 P. vivax infections 
were successfully treated with CQ and primaquine [251]. We also reported 2 pvmdr1 gene 
copies in one sample (with 976Y). These findings should be interpreted with caution as 
neither mefloquine nor artesunate are commonly used in Honduras [213]. It may however 
suggest the natural occurrence of this genetic change in Honduras. 
Haplotypes Y976F F1076L Number (Proportion %) 
1 Y F 29 (71) 
2 Y L 1 (2) 
3 F F 3 (7) 
4 F L 4 (10) 
5 Y ND 4 (10) 
Table 7 - Pvmdr1 Y976F and F1076L haplotype proportions. 
Resistance associated alleles are shown in bold. ND Not Determined 
4.2.2 P. vivax dihydrofolate reductase and P. vivax dihydropteroate synthase. 
Double (57L+117N), triple (57L+58R+117N) and quadruple (57L+58R+61M+117T) 
pvdhfr mutations have been associated with SP resistant P. vivax [226, 228, 295]. In paper I 
we report double mutation 57L + 58R in 2/57 (3%) samples. Allele Proportions are 
presented in table 8. Similar proportions have been reported in Asia but not in South 
America [133, 226, 228, 296-299]. Our results may suggest a degree of tolerance but 
probably not resistance to SP that should be efficacious for treatment of P. vivax in 
Honduras [129]. However, for P. vivax only CQ is used in Mesoamerica and the efficacy of 
SP has not been assessed in the area [58]. Finding the double mutation despite a probably 
low consumption of SP suggests that resistance might develop rapidly if SP usage 
increases. A possible explanation for the occurrence of 57L and 58R despite the low use of 
SP for malaria might be that trimethoprim/sulfamethoxazole is the first line drug for 
treatment of acute respiratory tract infections in Honduras [300]. 
 
Alleles F57L S58R T61M S117N/T Number (Proportion %) 
1 F S T S 57 (97) 
2 L R T S 2 (3) 
Table 8 – Pvdhfr F57L, S58R, T61M and S117N/T haplotype proportions.  
Resistance associated alleles are shown in bold 
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 5 CONCLUSIONS  
Overall Conclusion 
Samples from a previously treatment naïve area, areas of no and limited drug resistance 
despite considerable drug exposure and areas of established high level drug resistance 
collected between 1978 and 2012 were analysed in this thesis and provide novel insights into 
the selective effects of antimalarials on known and putative genetic markers of antimalarial 
drug resistance. 
Paper I 
In P. falciparum infections originating in Honduras only SNPs linked to chloroquine or 
sulphadoxine-pyrimethamine sensitivity were found indicating that chloroquine and 
sulphadoxine-pyrimethamine should remain efficacious. 
Chloroquine and sulphadoxine-pyrimethamine resistance associated SNPs were found in 
patients that contracted P. falciparum overseas highlighting the risk of drug resistance being 
imported to and spreading in Honduras.  
In P. vivax infections contracted in Honduras genetic polymorphisms associated with 
chloroquine and sulphadoxine-pyrimethamine tolerance were found in eight (13%) and two 
(3%) samples, respectively, suggesting that a degree of tolerance may exist in the country. 
Paper II 
The pfvp2 V405, K582 and P711 alleles were predominant throughout the eight countries 
studied. 
An association between the pfvp2 405V, 582K and 711P haplotype and pfcrt 76T was 
detected. These observations are in line with previous data indicating that PfVP2 may have a 
role in chloroquine resistance. However, pfvp2 SNPs were only found in 20/385 patient 
samples. The correlations found should therefore be interpreted with caution. 
Paper III 
In line with the continued efficacy of chloroquine, resistance associated SNPs in pfcrt were 
not widespread and were not found in pfmdr1 in Liberia despite 2 years of monthly 
intermittent presumptive therapy. 
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 The pfcrt 72-76 haplotype CVIET possibly developed de-novo but without the downstream 
pfcrt SNPs commonly found throughout CQR genotypes in Africa today.  
The PYR resistance associated SNP pfdhfr 108N probably existed prior to the introduction of 
PYR or SP in Liberia. 
Reduced frequency of pfdhfr 108N coincident with evidence of in vivo PYR resistance 
suggests that decreased susceptibility to PYR developed through mechanisms other than 
previously described SNPs in pfdhfr. 
Paper IV 
Pfcrt 76T accumulated during the high transmission season indicating that it provided a 
selective advantage after 2007. This was probably largely driven by quinine that was as 
commonly used as AL. 
P. falciparum parasite densities were lower with pfcrt 76T compared to pfcrt K76 suggesting 
a loss of fitness. 
The pfmdr1 86 + 184 NF and probably 1246D haplotype frequency increased between 2003 
and 2012 possibly driven by AL. 
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 6 FUTURE 
Our finding of the pfcrt 72-76 CVIET haplotype in a Liberian from 1978 requires further 
investigation as no other downstream SNPs occurred in the same sample. Microsatelites 
analysis will help to determine the origin of this sample. 
The intriguing finding of decreased pfdhfr 108N frequency concurrently with in vivo 
pyrimethamine resistance warrants further study. The first step will be to determine the 
presence of amplifications of the pfdhfr or GTP-cyclohydrolase (gch1) and SNPs in the 
pfmrp2 genes. 
It would also be very interesting to further assess the occurrence of polymorphisms associated 
with drug resistance in the collection of Liberian samples from 1977 to 1989. 
We have started an in vitro study to determine if P. falciparum are able to “shut down” when 
stressed. When both CQ sensitive and resistant P. falciparum are exposed to high CQ 
concentrations for periods of up to one week, very few small dots generally considered to be 
dead parasites remain. When these dots are followed for a long enough period of time they 
often revive. A hypothesis to explain this finding is that P. falciparum have an innate ability 
to shut down all non-essential systems and thereby survive. This could in turn explain why P. 
falciparum survive treatment even when adequate concentrations of a drug to which they are 
not resistant are achieved. Similar mechanisms have been described in bacteria and are 
believed to be a survival response to for example lack of essential nutrients. 
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